Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.

Epigenomics - 1 Jul 2016

Garrett-Bakelman Francine E, Melnick Ari M

Abstract excerpt

Aberrant epigenomic programming is a hallmark of acute myeloid leukemia. This is partially due to somatic mutations that perturb cytosine methylation, histone post-translational modifications and transcription factors. Remarkably, mutations in the IDH1 and IDH2 genes perturb the epigenome through all three of these mechanisms. Mutant IDH enzymes produce high levels of the oncometabolite (R)-2-hydroxyglutarate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenesis, Genetic
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to IDH1 gene

Share to IDH2 gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Phenotype

Share to Transcription, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 27431380
DOI: 10.2217/epi-2016-0008
PMCID: PMC5066133

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.PMID 27431380Read ↗

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

The role of IDH mutations in acute myeloid leukemia.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Semantic proximity Read ↗

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.Semantic proximity Read ↗

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.Semantic proximity Read ↗

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.